<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1153">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04344756</url>
  </required_header>
  <id_info>
    <org_study_id>APHP200389-6</org_study_id>
    <nct_id>NCT04344756</nct_id>
  </id_info>
  <brief_title>Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort</brief_title>
  <acronym>CORIMMUNO-COAG</acronym>
  <official_title>Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-COAG Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) and causes
      substantial morbidity and mortality. There is currently no vaccine to prevent Covid-19 or
      infection with SARS-CoV-2 or therapeutic agent to treat COVID-19.

      This protocol CORIMUNO19-COAG will evaluate the efficacy and safety of active anticoagulation
      using heparin: Tinzaparin (INNOHEP®) or unfractionated heparin (Calciparine®, Héparine
      Sodique Choay®) in COVID-19 patients hospitalized in conventional or intensive care units.

      It will use a phase 2 randomized open-label multicentre clinical trial, where patients will
      be randomly allocated to anticoagulation versus Standard of Care.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 20, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized clinical trial with 2 parallels arms, 1:1, stratified on disease severity (ventilation or not)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival without ventilation (VNI or mechanical ventilation)</measure>
    <time_frame>day 14</time_frame>
    <description>group 1</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ventilator free survival</measure>
    <time_frame>day 28</time_frame>
    <description>group 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>World Health Organisation(WHO) progression scale ≤5</measure>
    <time_frame>day 4</time_frame>
    <description>range from 0 (healthy) to 10 (death) values below or equal to 5 correspond to the absence of any oxygen supply beside nasal or facial mask</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>World Health Organisation(WHO) progression scale</measure>
    <time_frame>day 4, 7 and 14</time_frame>
    <description>range from 0 (healthy) to 10 (death)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>day 14, 28 and 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to oxygenation supply independency</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to ventilator (non invasive or invasive)</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of acute kidney injury</measure>
    <time_frame>day 28</time_frame>
    <description>according to Acute Kidney Injury (AKIN) classification system</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to Renal Replacement Therapy (RRT) initiation</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of clinically overt pulmonary embolism or proximal deep vein thrombosis</measure>
    <time_frame>day 14 and day 90</time_frame>
    <description>confirmed by objective testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinically overt arterial thrombosis</measure>
    <time_frame>day 14 and day 90</time_frame>
    <description>confirmed by objective testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of unscheduled central venous catheter replacement for catheter dysfunction</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of central venous catheter-related deep vein thrombosis (CVC-DVT)</measure>
    <time_frame>day 28</time_frame>
    <description>as a thrombus extending from the catheter into the lumen of the deep vein where the catheter is inserted diagnosed with radiologic imaging in case of a clinical suspicion of upper/lower limb DVT or pulmonary embolism or compulsory catheter removal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of unscheduled indwelling arterial catheter replacement for catheter dysfunction</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of acute clotting leading to the replacement the renal replacement therapy circuit stratified by regional citrate anticoagulation or not</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to acute clot formation within the oxygenator (acute oxygenator thrombosis, AOT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to acute clot formation within the pump head (pump head thrombosis, PHT) leading to the exchange of an extracorporeal membrane oxygenation (ECMO) system</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">808</enrollment>
  <condition>COVID19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Active Coagulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control patients will receive the best standard of care and a subcutaneous preventive anticoagulation for at least 14 days with enoxaparin 4000 IU/24h, tinzaparin 3500 IU/24h or dalteparin 5000 IU/24h if creatinine clearance (Cockcroft) ≥ 30mL/min or unfractionated heparin 5000 IU/12h if creatinine clearance &lt; 30mL/min.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tinzaparin or unfractionated heparin</intervention_name>
    <description>Tinzaparin INNOHEP ® 175 IU/kg/24h for 14 days if creatinine clearance Cockcroft ≥ 20mL/min, Otherwise unfractionated heparin (Calciparine®, Héparine Sodique Choay®) subcutaneously or intravenous with an anti-Xa target between 0.5 and 0.7 IU/mL for 14 days</description>
    <arm_group_label>Active Coagulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. group 1 : patients not requiring ICU at admission with mild disease to severe
             pneumopathy according to The Who Criteria of severity of COVID pneumopathy, and with
             symptom onset before 14 days, with need for oxygen but No non-invasive ventilation
             (NIV) or High flow

          2. group 2 :

               -  Respiratory failure AND requiring mechanical ventilation

               -  WHO progression scale ≥ 6

               -  No do-not-resuscitate order (DNR order)

        Exclusion Criteria:

          -  Patients with contraindications to anticoagulation

               1. Congenital hemorrhagic disorders

               2. Hypersensitivity to tinzaparin or UHF or to any of the excipients

               3. Current or history of immune-mediated heparin-induced thrombocytopenia

               4. Active major haemorrhage or conditions predisposing to major haemorrhage. Major
                  haemorrhage is defined as fulfilling any one of these three criteria: a) occurs
                  in a critical area or organ (e.g. intracranial, intraspinal, intraocular,
                  retroperitoneal, intra-articular or pericardial, intra-uterine or intramuscular
                  with compartment syndrome), b) causes a fall in haemoglobin level of 20 g/L (1.24
                  mmol/L) or more, or c) leads to transfusion of 2 or more units of whole blood or
                  red blood cells.

               5. Septic endocarditis

          -  Patients with need for anticoagulant therapy. For example: atrial fibrillation, venous
             thromboembolism, mechanical valve, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tristan Mirault</last_name>
    <phone>1 56 09 50 41</phone>
    <phone_ext>33</phone_ext>
    <email>tristan.mirault@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Luc Diehl</last_name>
    <email>jean-luc.diehl@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Réanimation hôpital Louis Mourier</name>
      <address>
        <city>Colombes</city>
        <state>Hauts De Seine</state>
        <zip>92701</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Damien Roux, MD PhD</last_name>
      <phone>1 47 60 61 62</phone>
      <phone_ext>33</phone_ext>
      <email>damien.roux@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>réanimation hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Frédéric Penne, MD PhD</last_name>
      <phone>1 58 41 25 27</phone>
      <phone_ext>33</phone_ext>
    </contact>
  </location>
  <location>
    <facility>
      <name>Médecine vasculaire, Hôpital Européen Georges Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>April 14, 2020</last_update_submitted>
  <last_update_submitted_qc>April 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Tinzaparin</mesh_term>
    <mesh_term>Heparin, Low-Molecular-Weight</mesh_term>
    <mesh_term>Dalteparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

